Key result
Current and prospective heart failure therapies target multiple molecular pathways involved in cardiac remodeling to interrupt or reverse disease progression.
This review summarizes the molecular targets and mechanisms of current and emerging therapies for heart failure.
May inform multi-pathway HF trial design; leaves open which targets yield net clinical benefit.
Heart failure (HF) is a vicious circle in which an original insult leading to mechanical cardiac dysfunction initiates multiple morphological, biochemical and molecular pathological alterations referred to as cardiac remodelling. Remodelling leads to further deterioration of cardiac function and functional reserve. Interrupting or reversing cardiac remodelling is a major therapeutic goal of HF therapies. The role of molecules and molecular pathways in cardiac remodelling and HF has been extensively studied. Multiple approaches are now used or investigated in HF therapy, including pharmacological therapy, device therapy, gene therapy, cell therapy and biological therapy targeting cytokines and growth factors. This review explores the molecular targets and molecular bases of current and prospective therapies in HF.
No takes yet. Share an insight, caveat, or question.
Chemaly et al. (2013) conducted a review in Heart failure. Heart failure therapies (pharmacological, device, gene, cell, and biological) was evaluated. Current and prospective heart failure therapies target multiple molecular pathways involved in cardiac remodeling to interrupt or reverse disease progression.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: